Interaction study between nifedipine and recombinant tissue‐type plasminogen activator in healthy subjects
1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue‐ type plasminogen activator (rt‐PA). 2. The purpose of this randomized, double‐blind, placebo‐controlled, three‐way, cross‐over investigation was to determine t...
Saved in:
Published in | British journal of clinical pharmacology Vol. 36; no. 2; pp. 99 - 104 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article Conference Proceeding |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
01.08.1993
Blackwell Science |
Subjects | |
Online Access | Get full text |
ISSN | 0306-5251 1365-2125 |
DOI | 10.1111/j.1365-2125.1993.tb04203.x |
Cover
Abstract | 1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue‐ type plasminogen activator (rt‐PA). 2. The purpose of this randomized, double‐blind, placebo‐controlled, three‐way, cross‐over investigation was to determine the effect of nifedipine (20 mg orally), a compound that increases liver blood flow, on plasma concentrations of steady state endogenous and recombinant tissue‐type plasminogen activator (t‐ PA and rt‐PA) (35 mg of rt‐PA over 2 h) in nine healthy male volunteers. 3. Nifedipine increased liver blood flow by 95% (42‐167%) (mean (95% confidence interval)) as assessed by indocyanine green (ICG, 0.5 mg kg‐1 i.v. bolus injection) clearance. 4. Nifedipine did not influence the plasma concentrations of total rt‐PA antigen and activity as evaluated by the areas under the rt‐PA curves from 30 min (time at which nifedipine was ingested) to 90 min during the rt‐PA infusion (P > 0.05) and by analysis of a possible treatment x time interaction (P > 0.05). In addition, the plasma concentrations of endogenous t‐PA remained unchanged when nifedipine was given alone. 5. In conclusion, by using nifedipine as a model compound it was demonstrated that the combination of rt‐PA and a compound which increases liver blood flow probably does not lead to substantial changes in plasma concentrations of rt‐PA. |
---|---|
AbstractList | 1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue‐ type plasminogen activator (rt‐PA). 2. The purpose of this randomized, double‐blind, placebo‐controlled, three‐way, cross‐over investigation was to determine the effect of nifedipine (20 mg orally), a compound that increases liver blood flow, on plasma concentrations of steady state endogenous and recombinant tissue‐type plasminogen activator (t‐ PA and rt‐PA) (35 mg of rt‐PA over 2 h) in nine healthy male volunteers. 3. Nifedipine increased liver blood flow by 95% (42‐167%) (mean (95% confidence interval)) as assessed by indocyanine green (ICG, 0.5 mg kg‐1 i.v. bolus injection) clearance. 4. Nifedipine did not influence the plasma concentrations of total rt‐PA antigen and activity as evaluated by the areas under the rt‐PA curves from 30 min (time at which nifedipine was ingested) to 90 min during the rt‐PA infusion (P > 0.05) and by analysis of a possible treatment x time interaction (P > 0.05). In addition, the plasma concentrations of endogenous t‐PA remained unchanged when nifedipine was given alone. 5. In conclusion, by using nifedipine as a model compound it was demonstrated that the combination of rt‐PA and a compound which increases liver blood flow probably does not lead to substantial changes in plasma concentrations of rt‐PA. 1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue-type plasminogen activator (rt-PA). 2. The purpose of this randomized, double-blind, placebo-controlled, three-way, cross-over investigation was to determine the effect of nifedipine (20 mg orally), a compound that increases liver blood flow, on plasma concentrations of steady state endogenous and recombinant tissue-type plasminogen activator (t-PA and rt-PA) (35 mg of rt-PA over 2 h) in nine healthy male volunteers. 3. Nifedipine increased liver blood flow by 95% (42-167%) (mean (95% confidence interval)) as assessed by indocyanine green (ICG, 0.5 mg kg-1 i.v. bolus injection) clearance. 4. Nifedipine did not influence the plasma concentrations of total rt-PA antigen and activity as evaluated by the areas under the rt-PA curves from 30 min (time at which nifedipine was ingested) to 90 min during the rt-PA infusion (P > 0.05) and by analysis of a possible treatment x time interaction (P > 0.05). In addition, the plasma concentrations of endogenous t-PA remained unchanged when nifedipine was given alone. 5. In conclusion, by using nifedipine as a model compound it was demonstrated that the combination of rt-PA and a compound which increases liver blood flow probably does not lead to substantial changes in plasma concentrations of rt-PA.1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue-type plasminogen activator (rt-PA). 2. The purpose of this randomized, double-blind, placebo-controlled, three-way, cross-over investigation was to determine the effect of nifedipine (20 mg orally), a compound that increases liver blood flow, on plasma concentrations of steady state endogenous and recombinant tissue-type plasminogen activator (t-PA and rt-PA) (35 mg of rt-PA over 2 h) in nine healthy male volunteers. 3. Nifedipine increased liver blood flow by 95% (42-167%) (mean (95% confidence interval)) as assessed by indocyanine green (ICG, 0.5 mg kg-1 i.v. bolus injection) clearance. 4. Nifedipine did not influence the plasma concentrations of total rt-PA antigen and activity as evaluated by the areas under the rt-PA curves from 30 min (time at which nifedipine was ingested) to 90 min during the rt-PA infusion (P > 0.05) and by analysis of a possible treatment x time interaction (P > 0.05). In addition, the plasma concentrations of endogenous t-PA remained unchanged when nifedipine was given alone. 5. In conclusion, by using nifedipine as a model compound it was demonstrated that the combination of rt-PA and a compound which increases liver blood flow probably does not lead to substantial changes in plasma concentrations of rt-PA. |
Author | Cohen, AF Schoemaker, HC Soons, PA Boer, A Breimer, DD Kroon, JM Kluft, C Kasper, FJ |
AuthorAffiliation | Centre for Human Drug Research, Leiden, The Netherlands |
AuthorAffiliation_xml | – name: Centre for Human Drug Research, Leiden, The Netherlands |
Author_xml | – sequence: 1 givenname: A surname: Boer fullname: Boer, A – sequence: 2 givenname: C surname: Kluft fullname: Kluft, C – sequence: 3 givenname: FJ surname: Kasper fullname: Kasper, FJ – sequence: 4 givenname: JM surname: Kroon fullname: Kroon, JM – sequence: 5 givenname: HC surname: Schoemaker fullname: Schoemaker, HC – sequence: 6 givenname: DD surname: Breimer fullname: Breimer, DD – sequence: 7 givenname: PA surname: Soons fullname: Soons, PA – sequence: 8 givenname: AF surname: Cohen fullname: Cohen, AF |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4895158$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/8398589$$D View this record in MEDLINE/PubMed |
BookMark | eNqVUstu1DAUtVBRmQ58ApKFEOomwY7jJGbBa8SjUiVYwNpynJuOR4k9xE7b7PoJfCNfgqOJRsACgTe2fM49vvf4nKET6ywg9ISSlMb1fJdSVvAkoxlPqRAsDTXJM8LS23todYRO0IowUiQ84_QBOvN-RwhltOCn6LRiouKVWKHuwgYYlA7GWezD2Ey4hnADYLE1LTRmbyxgZRs8gHZ9bayyAQfj_Qg_7r6HaQ943ynfG-uuYtGsdK2CG7CxeAuqC9sJ-7HegQ7-Ibrfqs7Do2Vfo6_v333ZfEwuP3242Ly5TDRngiUiI3WjM16xXBRZSxoRb_O2IFQ3FW9aVma0VQUrdAkALC9UBrUCwvNG6IxptkYvD7r7se6h0WDDoDq5H0yvhkk6ZeTviDVbeeWuZfQu5yWNAs8WgcF9G8EH2RuvoeuUBTd6WXJRkjw6v0bnfyXSkrO8JHGQSH38a1PHbpaviPjTBVdeq64dlNXGH2l5JTiNlqzRiwNND877AdojgxI5p0Pu5jG4nCMg53TIJR3yNha__qNYm6Dmv482mO7fJF4dJG5MB9N_PC7fbj7PJ_YTHMTaNw |
CODEN | BCPHBM |
CitedBy_id | crossref_primary_10_2165_00002018_200023050_00004 crossref_primary_10_1016_j_rpth_2024_102518 crossref_primary_10_1002_phar_2025 |
Cites_doi | 10.1161/01.CIR.43.2.205 10.2165/00003495-198530030-00002 10.1111/j.1365-2125.1984.tb05003.x 10.1182/blood.V66.4.835.835 10.2165/00003088-197904060-00003 10.1002/jps.2600710205 10.1038/clpt.1986.169 10.1056/NEJM197805252982102 10.1055/s-0038-1648385 10.1055/s-0038-1657277 10.1161/01.CIR.73.2.347 10.1056/NEJM198504043121437 |
ContentType | Journal Article Conference Proceeding |
Copyright | 1993 The British Pharmacological Society 1993 INIST-CNRS |
Copyright_xml | – notice: 1993 The British Pharmacological Society – notice: 1993 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 8FD FR3 P64 RC3 7X8 5PM |
DOI | 10.1111/j.1365-2125.1993.tb04203.x |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Engineering Research Database Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | CrossRef Genetics Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1365-2125 |
EndPage | 104 |
ExternalDocumentID | PMC1364571 8398589 4895158 10_1111_j_1365_2125_1993_tb04203_x BCP4203 |
Genre | article Clinical Trial Randomized Controlled Trial Journal Article |
GrantInformation_xml | – fundername: British Pharmacological Society. Clinical Pharmacology Section |
GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1OC 23N 24P 2WC 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAHQN AAIPD AAMNL AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AOIJS ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DU5 E3Z EBS EJD EMOBN ESX EX3 F00 F01 F04 F5P FIJ FUBAC G-S G.N GODZA GX1 H.X HF~ HGLYW HYE HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RPM RX1 SUPJJ TEORI TR2 UB1 V8K W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT AAYXX AEYWJ AGHNM AGYGG CITATION AAMMB AEFGJ AGXDD AIDQK AIDYY IQODW CGR CUY CVF ECM EIF NPM 8FD FR3 P64 RC3 7X8 5PM |
ID | FETCH-LOGICAL-c5393-920bdc25834962f0d93934f601cd85df3721fa636c7eee346a2ebae054d9c23c3 |
ISSN | 0306-5251 |
IngestDate | Thu Aug 21 18:31:49 EDT 2025 Fri Sep 05 06:59:38 EDT 2025 Thu Sep 04 17:39:11 EDT 2025 Wed Feb 19 02:35:18 EST 2025 Mon Jul 21 09:11:42 EDT 2025 Thu Apr 24 23:11:03 EDT 2025 Tue Jul 01 02:29:42 EDT 2025 Wed Jan 22 17:04:41 EST 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Human Intravenous administration Pyridine(dihydro) derivative Oral administration Drug interaction Normal Pharmacokinetics Blood plasma |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor CC BY 4.0 |
LinkModel | OpenURL |
MeetingName | British Pharmacological Society. Clinical Pharmacology Section. Meeting |
MergedId | FETCHMERGED-LOGICAL-c5393-920bdc25834962f0d93934f601cd85df3721fa636c7eee346a2ebae054d9c23c3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 ObjectType-Undefined-3 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2125.1993.tb04203.x |
PMID | 8398589 |
PQID | 1753470349 |
PQPubID | 23462 |
PageCount | 6 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_1364571 proquest_miscellaneous_75970499 proquest_miscellaneous_1753470349 pubmed_primary_8398589 pascalfrancis_primary_4895158 crossref_primary_10_1111_j_1365_2125_1993_tb04203_x crossref_citationtrail_10_1111_j_1365_2125_1993_tb04203_x wiley_primary_10_1111_j_1365_2125_1993_tb04203_x_BCP4203 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | August 1993 |
PublicationDateYYYYMMDD | 1993-08-01 |
PublicationDate_xml | – month: 08 year: 1993 text: August 1993 |
PublicationDecade | 1990 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: London – name: England |
PublicationTitle | British journal of clinical pharmacology |
PublicationTitleAlternate | Br J Clin Pharmacol |
PublicationYear | 1993 |
Publisher | Blackwell Publishing Ltd Blackwell Science |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell Science |
References | 1971; 43 1982; 48 1971; 71 1979; 298 1986; 40 1986; 73 1984; 17 1979; 4 1985; 312 1985; 30 1961; 21 1985; 66 1992; 67 Verheijen JH (e_1_2_1_11_2) 1982; 48 Caesar J (e_1_2_1_10_2) 1961; 21 e_1_2_1_6_2 e_1_2_1_7_2 e_1_2_1_4_2 e_1_2_1_5_2 e_1_2_1_3_2 e_1_2_1_12_2 Boer A (e_1_2_1_2_2) 1992; 67 e_1_2_1_13_2 e_1_2_1_14_2 e_1_2_1_8_2 e_1_2_1_9_2 |
References_xml | – volume: 71 start-page: 157 year: 1971 end-page: 160 article-title: High pressure liquid chromatographic analysis of indocyanine green publication-title: J pharm Sci – volume: 21 start-page: 43 year: 1961 end-page: 57 article-title: The use of indocyanin green in the measurement of hepatic blood flow and as a test of hepatic function publication-title: Clin Sci – volume: 298 start-page: 1160 year: 1979 end-page: 1163 article-title: Lidocaine kinetics predicted by indocyanine green clearance publication-title: New Engl J Med – volume: 40 start-page: 239 year: 1986 end-page: 242 article-title: Changes in antipyrin and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy publication-title: Clin Pharmac Ther – volume: 43 start-page: 205 year: 1971 end-page: 211 article-title: Interrelationships of hepatic blood flow, cardiac output, and blood levels of lidocaine in man publication-title: Circulation – volume: 17 start-page: 83 year: 1984 end-page: 85 article-title: Nifedipine increases and glyceryl trinitrate decreases apparent liver blood flow in normal subjects publication-title: Br J clin Pharmac – volume: 73 start-page: 347 year: 1986 end-page: 352 article-title: Acute coronary reocclusion after thrombolysis with recombinant human tissue‐type plasminogen activator: prevention by a maintenance infusion publication-title: Circulation – volume: 312 start-page: 932 year: 1985 end-page: 936 article-title: The thrombolysis in myocardial infarction (TIMI) trial publication-title: New Engl J Med – volume: 67 start-page: 83 year: 1992 end-page: 87 article-title: Liver blood flow as a major determinant of the clearance of recombinant human tissue‐type plasminogen activator publication-title: Thromb Haemostas – volume: 48 start-page: 266 year: 1982 end-page: 269 article-title: A simple, sensitive spectrophotometric assay for extrinsic (tissue‐type) plasminogen activator applicable to measurement in plasma publication-title: Thromb Haemostas – volume: 66 start-page: 835 year: 1985 end-page: 839 article-title: Tissue plasminogen activator release in vivo in response to vasoactive agents publication-title: Blood – volume: 30 start-page: 182 year: 1985 end-page: 274 article-title: Nifedipine—A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischemic heart disease, hypertension and related cardiovascular disorders publication-title: Drugs – volume: 4 start-page: 433 year: 1979 end-page: 448 article-title: Drug kinetics and hepatic blood flow publication-title: Clin Pharmacokin – ident: e_1_2_1_3_2 doi: 10.1161/01.CIR.43.2.205 – ident: e_1_2_1_7_2 doi: 10.2165/00003495-198530030-00002 – ident: e_1_2_1_9_2 doi: 10.1111/j.1365-2125.1984.tb05003.x – ident: e_1_2_1_6_2 doi: 10.1182/blood.V66.4.835.835 – ident: e_1_2_1_5_2 doi: 10.2165/00003088-197904060-00003 – ident: e_1_2_1_12_2 doi: 10.1002/jps.2600710205 – ident: e_1_2_1_8_2 doi: 10.1038/clpt.1986.169 – ident: e_1_2_1_4_2 doi: 10.1056/NEJM197805252982102 – volume: 21 start-page: 43 year: 1961 ident: e_1_2_1_10_2 article-title: The use of indocyanin green in the measurement of hepatic blood flow and as a test of hepatic function publication-title: Clin Sci – volume: 67 start-page: 83 year: 1992 ident: e_1_2_1_2_2 article-title: Liver blood flow as a major determinant of the clearance of recombinant human tissue‐type plasminogen activator publication-title: Thromb Haemostas doi: 10.1055/s-0038-1648385 – volume: 48 start-page: 266 year: 1982 ident: e_1_2_1_11_2 article-title: A simple, sensitive spectrophotometric assay for extrinsic (tissue‐type) plasminogen activator applicable to measurement in plasma publication-title: Thromb Haemostas doi: 10.1055/s-0038-1657277 – ident: e_1_2_1_14_2 doi: 10.1161/01.CIR.73.2.347 – ident: e_1_2_1_13_2 doi: 10.1056/NEJM198504043121437 |
SSID | ssj0013165 |
Score | 1.4487329 |
Snippet | 1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue‐ type plasminogen... 1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue-type plasminogen... 1. In a previous study it was demonstrated that a decrease in liver blood flow produced a decrease in clearance of recombinant human tissue- type plasminogen... |
SourceID | pubmedcentral proquest pubmed pascalfrancis crossref wiley |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 99 |
SubjectTerms | Adult Biological and medical sciences Blood Pressure - drug effects Blood. Blood coagulation. Reticuloendothelial system Double-Blind Method Drug Interactions Heart Rate - drug effects Humans Indocyanine Green - metabolism Kinetics Liver Circulation - drug effects Male Medical sciences Nifedipine - pharmacology Pharmacology. Drug treatments Recombinant Proteins - blood Tissue Plasminogen Activator - blood |
Title | Interaction study between nifedipine and recombinant tissue‐type plasminogen activator in healthy subjects |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2125.1993.tb04203.x https://www.ncbi.nlm.nih.gov/pubmed/8398589 https://www.proquest.com/docview/1753470349 https://www.proquest.com/docview/75970499 https://pubmed.ncbi.nlm.nih.gov/PMC1364571 |
Volume | 36 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9NAEF2FckHiwEcrDBQWCfWSOrK9a3tzpKVRaYBEkEi9WfbaFkHUiUiCCL-FH8vMerPetImgXCzLX4n1nmd3ZmfeEPK6THmcSha6gHDpchlJ-KQ4c4UsozLPhV-mGBr48DE6H_OLy_Cy1fptZS0tF1lH_tpaV_I_qMIxwBWrZG-BrHkoHIB9wBe2gDBsb2K8dahZaxJZAhCm1nHWqFKvbGaoIKBuEa7UZU2yFua55NjMul5TQGf5KlOpMu2FAshVEdsZzLivJtUU_pfS4viBjjsGTuqiylV7vswwvNP0rD9rnwzqlIvGwr8f90YbYdr-m8_D-qJep1mt6n8aDFQqwkVHR25zXbTHTIbc9VikNliWkQOXBZxhLTqrLXItiaKZF1jmte6lpAdq3bd49xigEvhgAocVmQxD4Dzw2Do71BbevjYgmjRFLmD-GYo75G7AYoGNQd6-6zdrVL5qVGreQEva6jyxHT--Mf25P0vnwIeybqGyzce5mapru1BqDjR6QPab6lA6NGR8SFpF9YgcDWu2rY7pqCnpmx_TIzq0ePiYfLXoRxX9qKYfbehHgX7Uoh-16Ect-lFDPzqpqKYfXdNvn4x7Z6PTc1c3_HBlyIA13cDLchmEArsYBKWXd-EoLyPPl7kI85LFAdiOiEUyLoqC8SgNiiwtwOvIuzJgkh2QvWpaFU8I5WkcFYXvxVkq4AmAXhpFXGBlNQs8kTuku8YhkVoNH5uyfEssrxgwTBDDBDFMNIbJT4cwc--s1oT5p7sON-A2t2qWOeTVGv4ETDyu26VVMV3OExTT5TEKSTnk5Y5r4rAbY_TCIQc1YczjwQMSoYAT8QaTzHnUl988U02-KJ15H1MUYt8hQnHuFu-anJwOce_pX975GbnXmIvnZG_xfVkcwiR_kb1Q39ofw8P9Bg |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=proceeding&rft.title=British+journal+of+clinical+pharmacology&rft.atitle=Interaction+study+between+nifedipine+and+recombinant+tissue-type+plasminogen+activator+in+healthy+subjects&rft.au=DE+BOER%2C+A&rft.au=KLUFT%2C+C&rft.au=KASPER%2C+F.+J&rft.au=KROON%2C+J.+M&rft.date=1993-08-01&rft.pub=Blackwell+Science&rft.issn=0306-5251&rft.volume=36&rft.issue=2&rft.spage=99&rft.epage=104&rft_id=info:doi/10.1111%2Fj.1365-2125.1993.tb04203.x&rft.externalDBID=n%2Fa&rft.externalDocID=4895158 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0306-5251&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0306-5251&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0306-5251&client=summon |